Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
Nature Cancer|February 19, 2025
Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma - a multicenter phase 2 trial (EPOC1802)Hideaki Bando, Shogo Kumagai, Daisuke Kotani, et al.
NPJ Precision Oncology|April 30, 2026
Preoperative ctDNA and tumor volume predict colorectal cancer recurrence after metastasis resectionHidekazu Oyoshi, Hideaki Bando, Riu Yamashita, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2024
A Tumor-Naïve ctDNA Assay Detects Minimal Residual Disease in Resected Stage II or III Colorectal Cancer and Predicts Recurrence: Subset Analysis from the GALAXY Study in CIRCULATE-JapanYoshiaki Nakamura, Kristiyana Kaneva, Christine Lo, et al.
JAMA Oncology|July 3, 2026
Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver MetastasesKozo Kataoka, Kazuma Ito, Yoshiaki Nakamura, et al.
NPJ Precision Oncology|January 19, 2026
Validation of a methylation-based, tissue-free MRD assay in colorectal cancer patients from the GALAXY studyYoshiaki Nakamura, Johannes G Reiter, Prashanthi Natarajan, et al.
Cancer Science|September 7, 2018
Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0)Kuniko Sunami, Hideaki Takahashi, Katsuya Tsuchihara, et al.
Nature Medicine|September 16, 2024
ctDNA-based molecular residual disease and survival in resectable colorectal cancerYoshiaki Nakamura, Jun Watanabe, Naoya Akazawa, et al.
JCO Precision Oncology|August 17, 2022
Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant TumorsMatthew Dankner, Yifan Wang, Rouhi Fazelzad, et al.
Nature Medicine|June 8, 2026
Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trialHideaki Bando, Jun Watanabe, Yusuke Takahashi, et al.
Pageof 9